Visiongain publishes Asthma & COPD Therapies Market 2020-2030 report

LONDON, Aug. 28, 2020 /PRNewswire/ -- Forecasts by Treatment (Bronchodilator Monotherapy (Anticholinergics (Spiriva, Atrovent, Eklira, Others), SABA (Ventolin, ProAir, Proventil, Xoponex, Others), LABA (Foradil, Arcapta/Onbrez, Brovana, Serevent, Others)), (Anti-Inflammatory Drugs (Corticosteroids (Pulmicort, Flixotide, QVAR, Asmanex, Others), Anti-Leukotrienes (Singulair, Others), Monoclonal Antibodies (Xolair, Cinqair, Nucala, Benralizumab, Lebrikizumab, Dupilumab)), Others, (Combination Drugs (Advair, Symbicort, Combivent, Dulera, Relvar/Breo, Others)), by Route of Administration (Oral, Inhaled, Others), by Point of Sale/Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Others), Geography (North America, Europe, Asia Pacific, Rest of the World) PLUS COVID-19 Impact Scenarios and Profiles of Leading Asthma & COPD Companies

COPD and Asthma Therapeutics – our new study reveals trends, R&D progress, and predicted revenues

Where is the COPD and asthma therapeutics market heading? If you are involved in this sector you must read this newly updated report. Visiongain's report shows you the potential revenues streams to 2030, assessing data, trends, opportunities and business prospects there.

Discover how to stay ahead

Our 310+ page report provides 370+ tables and charts/graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing COPD and Asthma Therapeutics Market. See how to exploit the opportunities.

Forecasts to 2030 and other analyses reveal the commercial prospects

• In addition to revenue forecasting to 2030, our new study provides you with recent results, growth rates, and market shares.

• You find original analyses, with business outlooks and developments.

• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), product profiles and commercial developments.

This Visiongain report includes data analysis and invaluable insight into how COVID-19 will affect your industry. Access this report today.

To access the data contained in this document please email [email protected]

To request sample pages from this report please email [email protected] or refer to our website: https://www.visiongain.com/report/asthma-copd-therapies-market-2020-2030/#download_sampe_div

Discover sales predictions for the world market and submarkets

By Treatment:

• Bronchodilator Monotherapy

– Anticholinergics: Spiriva, Atrovent, Eklira, Others

– SABA: Ventolin, ProAir, Proventil, Xoponex, Others

– LABA: Foradil, Arcapta/Onbrez, Brovana, Serevent, Others

• Anti-Inflammatory Drugs

– Corticosteroids: Pulmicort, Flixotide, QVAR, Asmanex, Others

– Anti-Leukotrienes: Singulair, Others

– Monoclonal Antibodies: Xolair, Cinqair, Nucala, Benralizumab, Lebrikizumab, Dupilumab

– Others

• Combination Drugs

– Advair

– Symbicort

– Combivent

– Dulera

– Relvar/Breo

– Others

By Route of Administration:

• Oral

• Inhaled

• Others

By Point of Sale/Distribution Channel:

• Retail pharmacies

• Hospital pharmacies

• Others

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 4 regional and 10 leading national markets:

By Region:

• North America

– U.S.

– Canada

• Europe

– Germany

– France

– UK

– Italy

– Spain

– Rest of Europe

• Asia Pacific

– China

– Japan

– India

– Rest of APAC

• Rest of the World

The report also includes profiles and for some of the leading companies in the COPD and asthma therapeutics Market, with a focus on this segment of these companies' operations.

There will be growth in both established and in developing countries. Our analyses show that the both developed and developing markets, U.S., Germany, UK and Japan, China in particular, will continue to achieve high revenue growth to 2030.

Leading companies and the potential for market growth

Overall world revenue for COPD and Asthma Therapeutics Market will surpass US$ xx million in 2020, our work calculates. We predict strong revenue growth through to 2030.

Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How the COPD and Asthma Therapeutics Market report helps you

In summary, our 310+ page report provides you with the following knowledge:

• Revenue forecasts to 2030 for COPD and Asthma Therapeutics Market, with forecasts for Treatment, Route of Administration, and Distribution Channel, each forecasted at a global and regional level– discover the industry's prospects, finding the most lucrative places for investments and revenues

• Revenue forecasts to 2030 for 4 regional and 10 key national markets – See forecasts for the COPD and Asthma Therapeutics market in North America, Europe, Asia-Pacific and Rest of the World. Also forecasted is the market in the US, Canada, Germany, France, UK, Italy, Spain, China, India, and Japan.

• Prospects for established firms and those seeking to enter the market– including company profiles for 12 of the major companies involved in the COPD and Asthma Therapeutics Market. Some of the company's profiles in this report include AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim, Teva, Merck, F. Hoffmann-La Roche AG.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.

To request a report overview of this report please email [email protected] or refer to our website: https://www.visiongain.com/report/asthma-copd-therapies-market-2020-2030/

Did you know that we also offer a report add-on service? Email [email protected] to discuss any customized research needs you may have.

Companies covered in the report include:

AstraZeneca

Boehringer Ingelheim

Cipla

F.Hoffmann-La Roche AG

GlaxoSmithKline

Merck

Mundipharma

Novartis

Pulmatrix

Respiratorius AB

Teva

TFF PHARMACEUTICALS, INC

List of Organizations Mentioned in the Report

American Lung Association

Asthma & Bronchitis Association of India

Asthma and Allergy Foundation of America

Asthma Society of India

Asthma.com

European Federation of Allergy and Airway Diseases

European Federation of Allergy and Airways Diseases

European Lung Foundation

European Respiratory Society

European Respiratory Society

National Heart, Lung, and Blood Institute

The American Academy of Allergy, Asthma & Immunology

The Asthma UK and British Lung Foundation Partnership

World Health Organization

To see a report overview please e-mail [email protected]

RELATED REPORTS:

Novel Coronavirus (COVID-19) Drugs in Development Market Forecast 2020-2030

Top 55 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market 2020

Biological Drug API Manufacturing Services World Industry and Market Forecast to 2029

Pharma Contract Manufacturing Market Report 2020-2030

Biopharmaceuticals Excipients Market 2020-2030

SOURCE Visiongain